“…Introduced by Boura et al (1959), bretylium tosylate blocks the sympathetic nervous system by its selective accumulation in sympathetic ganglia and post-ganglionic sympathetic fibres. Following on encouraging reports of clinical trials (Boura et al, 1959;Dollery et al, 1960a) there has been a considerable correspondence Lowther, 1960a, 1960b;Evanson and Sears, 1960;Lowe and Rosenheim, 1960;Somers, 1960a) recording unfavourable experiences with bretylium. Ultimately Dollery et al (1960b) abandoned the use of bretylium because of the high incidence of drug resistance.…”